Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,522,096
  • Shares Outstanding, K 2,511,031
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 20,398 M
  • EBITDA $ 24,897 M
  • 60-Month Beta 0.38
  • Price/Sales 3.09
  • Price/Cash Flow 8.38
  • Price/Book 4.13

Options Overview Details

View History
  • Implied Volatility 31.26% ( +0.72%)
  • Historical Volatility 33.21%
  • IV Percentile 78%
  • IV Rank 39.87%
  • IV High 53.48% on 04/10/25
  • IV Low 16.52% on 06/21/24
  • Put/Call Vol Ratio 0.70
  • Today's Volume 36,469
  • Volume Avg (30-Day) 50,616
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 823,572
  • Open Int (30-Day) 776,857

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 2.03
  • Number of Estimates 6
  • High Estimate 2.14
  • Low Estimate 1.94
  • Prior Year 2.28
  • Growth Rate Est. (year over year) -10.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.40 +4.85%
on 06/02/25
82.44 -4.10%
on 06/13/25
+1.09 (+1.40%)
since 05/20/25
3-Month
73.31 +7.84%
on 05/15/25
94.68 -16.50%
on 03/21/25
-15.67 (-16.54%)
since 03/20/25
52-Week
73.31 +7.84%
on 05/15/25
134.63 -41.28%
on 06/25/24
-50.61 (-39.03%)
since 06/20/24

Most Recent Stories

More News
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on...

AZN : 69.95 (-1.14%)
MRK : 79.06 (-0.29%)
PFE : 23.97 (+0.38%)
BMY : 46.86 (+0.04%)
Stocks Slightly Higher as Bond Yields Decline

The S&P 500 Index ($SPX ) (SPY ) today is up +0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.10%. June E-mini S&P futures (ESM25...

$SPX : 5,967.84 (-0.22%)
JPM : 275.00 (+0.38%)
ADI : 228.35 (-0.57%)
MRK : 79.06 (-0.29%)
ORCL : 205.17 (-2.70%)
$IUXX : 21,626.39 (-0.43%)
NQU25 : 21,844.75s (-0.46%)
AMGN : 289.33 (-0.10%)
BMY : 46.86 (+0.04%)
QQQ : 526.83 (-0.41%)
ZNU25 : 110-315s (+0.17%)
ESU25 : 6,018.00s (-0.27%)
2 Option Ideas to Consider this Wednesday for Bearish Traders

Today, we are using some moving average filters to find bullish stocks and then looking at a couple of different trade ideas.

MRK : 79.06 (-0.29%)
ADBE : 376.92 (-0.30%)
2 Dividend Stocks to Buy and Never Sell

JNJ : 149.79 (-0.62%)
MRK : 79.06 (-0.29%)
SMMT : 20.56 (+1.98%)
KVUE : 21.39 (+0.14%)
Stocks Tumble and Oil Surges on Middle East Jitters

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.84%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.00%. June E-mini...

UAL : 74.27 (-0.04%)
MPC : 169.12 (+1.02%)
DHI : 124.20 (+2.41%)
CVX : 149.55 (+0.92%)
MRK : 79.06 (-0.29%)
LVS : 41.68 (-0.24%)
$IUXX : 21,626.39 (-0.43%)
ALKS : 29.09 (-0.82%)
PFE : 23.97 (+0.38%)
ZNU25 : 110-315s (+0.17%)
OXY : 45.63 (+0.62%)
ESU25 : 6,018.00s (-0.27%)
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?

Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). Though the vaccine’s sales rose consistently till 2022,...

AZN : 69.95 (-1.14%)
MRK : 79.06 (-0.29%)
PFE : 23.97 (+0.38%)
SNY : 47.86 (+0.50%)
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025

The Dow Jones index could have fared better in May if not for these two stocks.

MRK : 79.06 (-0.29%)
$DOWI : 42,206.82 (+0.08%)
UNH : 302.01 (-1.69%)
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

Bristol Myers BMY is focused on developing drugs with presence in oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. BMY depends on label expansion of approved...

MRK : 79.06 (-0.29%)
AMGN : 289.33 (-0.10%)
BMY : 46.86 (+0.04%)
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024...

AZN : 69.95 (-1.14%)
MRK : 79.06 (-0.29%)
PFE : 23.97 (+0.38%)
BMY : 46.86 (+0.04%)
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility

NFLX : 1,231.41 (+0.75%)
MSFT : 477.40 (-0.59%)
GOOGL : 166.64 (-3.85%)
GOOG : 167.73 (-3.59%)
NVO : 73.77 (-0.32%)
MRK : 79.06 (-0.29%)
LLY : 762.73 (-2.84%)
VEEV : 280.08 (-0.48%)
AMZN : 209.69 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 81.10
2nd Resistance Point 80.51
1st Resistance Point 79.78
Last Price 79.06
1st Support Level 78.47
2nd Support Level 77.88
3rd Support Level 77.15

See More

52-Week High 134.63
Fibonacci 61.8% 111.21
Fibonacci 50% 103.97
Fibonacci 38.2% 96.73
Last Price 79.06
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar